Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04428203 · ClinicalTrials.gov registry record · Phase 1
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
A Phase 1 study, sponsored by Zin W Myint.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04428203: Completed Phase 1 study, sponsored by Zin W Myint.
NCT04428203 is a Phase 1 study that has completed, run by Zin W Myint. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04428203, a Phase 1 study, has completed, sponsored by Zin W Myint.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients. The study consists of a dose escalation part and dose expansion part. The dose expansion part of the study will use the maximum tolerated dose (MTD) determined in the dose escalation part to assess the activity, safety and tolerability of the investigational product in patients with biochemically recurrent prostate cancer after localized therapy with either surgery or radiation.
Interventions
- DRUG Epidiolex Oral Liquid Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04428203
The ClinicalTrials.gov registry entry for NCT04428203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zin W Myint, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epidiolex Oral Liquid Product is the first listed.
NCT04428203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04428203 about?
NCT04428203 is a clinical study titled "Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer". The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients. The study consists of a dose escalation part and dose expansion part. The dose expansion part of the study will use the maximum tolerated dose (MTD) det...
What is the current status of trial NCT04428203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-08-03. Estimated completion is 2021-08-20.
What interventions are being tested in trial NCT04428203?
The interventions under investigation include: Epidiolex Oral Liquid Product (DRUG).
Who is sponsoring clinical trial NCT04428203?
This trial is sponsored by Zin W Myint, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.